Treatment-Induced Hair Shedding (Dread Shed) Associated with Androgenetic Alopecia Therapies
Main Article Content
Keywords
Dreadshed, Minoxidil, androgenetic alopecia, hair loss, nutraceutical, Female pattern hair loss
Abstract
Treatment-induced hair shedding, or “dread shed,” is an often discussed yet poorly defined phenomenon in androgenetic alopecia (AGA) management. Shedding was most consistently reported with topical and oral minoxidil, attributed to premature anagen induction or stress-induced telogen effluvium. Evidence for shedding with antiandrogens is limited, while platelet-rich plasma with microneedling and light based therapies were rarely associated. Nutraceutical trials generally showed improved hair parameters without a clear shedding phase, though early shedding may be underrecognized due to delayed efficacy assessments. Despite its prevalence in social media, “dread shed” remains underrepresented in literature, highlighting the need for further research to guide patient counseling.
References
2. Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3. doi:10.1016/j.jaad.2013.10.049
3. Stojadinovic O, Morrison B, Tosti A. Adverse effects of platelet-rich plasma and microneedling. Journal of the American Academy of Dermatology. 2020;82(2):501-502. doi:10.1016/j.jaad.2019.07.109
4. Ablon G, Kogan S. A Randomized, Double-Blind, Placebo-Controlled Study of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal, and Postmenopausal Women With Thinning Hair. J Drugs Dermatol. 2021;20(1):55-61. doi:10.36849/JDD.5701
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.